Diabetes

Investigators of a recent study said targeted interventions are needed to reduce the global burden, particularly in developing countries.

Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed the benefits of tirzepatide compared with semaglutide.

A study found that sending a letter to providers about standards of care and glucagon preparations could increase glucagon prescription rates.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses the benefits of glucagon and why pharmacists should be able to prescribe it.

Check out this list of our top 5 most read diabetes stories from the year 2024.

A conversation with Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, professor of pharmacy practice at Massachusetts College of Pharmacy and Health Sciences.

MannKind announced results from the INHALE-1 study that examined Afrezza in children and adolescents with diabetes.

Student pharmacists who wore a continuous glucose monitor had a higher average counseling score during an encounter with a patient and a higher overall confidence score.

Two posters presented at the meeting looked into the topic CGMs in diabetes care.

Denise Kelley, PharmD, BCPS, FASHP, joined Drug Topics to discuss various medications for chronic kidney disease and their common adverse reactions.

Research found that SGLT2 inhibitors were associated with a lower risk of major cardiovascular events or hospitalization for heart failure.

Medication alerts, nurse education, and pharmacist interventions led to lower hypoglycemic events every year after they were implemented.

Research also showed that the percentage of no-show appointments was slightly higher in a pre-virtual group compared to a post-virtual group.

Efficacy data for dapagliflozin and empagliflozin in a group of Asian patients were evaluated.

A recent study found that patients who consumed 5 or more servings a week of dark chocolate had a significantly lower rate of type 2 diabetes.

A recent study found that, among older adults who are generally healthy and not at high risk for type 2 diabetes, Vitamin D3 supplementation does not significantly reduce the risk of developing the disease.

A study found that patients with obesity who were diagnosed with type 2 diabetes aged 50 or younger had the highest risk of dementia.

Catch up on important diabetes news from November 2024.

A recent study found that there was a significant relationship between self-efficacy for disease control and the level of glycemic control.

Research presented at American Heart Association’s 2024 Scientific Sessions examined the SGLT inhibitor’s effect on systolic blood pressure.

Two posted presented at the American Heart Association’s 2024 Scientific Sessions explored empagliflozin among patients with type 2 diabetes and cardiovascular risk.

Three research posters presented at the American Heart Association’s 2024 Scientific Sessions looked into the use of SGLT-2 inhibitors in patients with type 2 diabetes and cardiovascular complications.

Patients with type 2 diabetes who had eating problems and higher levels of diabetes distress had worse time-in-range.

A study found that a continuous glucose monitor workflow led by a pharmacist led to reduced HbA1c levels.

A recent study found that with greater depression severity, metabolic and clinical characteristics such as HbA1c, fasting blood glucose, and triglyceride levels increased.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses a recent meta-analysis that evaluated the efficacy, safety, and clinical implications of insulin icodec.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses how insulin icodec differs from existing daily basal insulins and key things pharmacists need to know about the medication.

A recent study found the percentage of type 1 diabetes patients who were prescribed either GLP-1s or SGLT2 inhibitors increased from 0.7% to 8.3% between 2010 and 2023.

Investigators conducted a study to assess the impact of combined diet and exercise interventions in patients with type 2 diabetes.

Results of the SOUL clinical trial will be presented at a scientific meeting in 2025.